ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
作者信息
Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann W G, Quintás-Cardama A, Roulston D, Talpaz M, Peterson L F, Donato N J
出版信息
Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
Abstract
摘要
相似文献
1
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.ON012380，一种假定的BCR-ABL激酶抑制剂，在伊马替尼耐药细胞中具有独特的作用机制。
Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
2
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.所有对酪氨酸激酶抑制剂耐药的慢性髓性细胞对波纳替尼高度敏感。
Oncotarget. 2012 Dec;3(12):1557-65. doi: 10.18632/oncotarget.692.
3
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.将II型ATP竞争性抑制剂与BCR-ABL变构竞争性抑制剂联合用于治疗对伊马替尼敏感和耐药的慢性粒细胞白血病的有益效果。
Leukemia. 2010 Jul;24(7):1375-8. doi: 10.1038/leu.2010.107. Epub 2010 May 27.
4
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.伏立诺他（辛二酰苯胺异羟肟酸）与达沙替尼（BMS-354825）联合治疗可增强达沙替尼对甲磺酸伊马替尼敏感或甲磺酸伊马替尼耐药的慢性粒细胞白血病细胞的活性。
Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.
5
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.慢性髓性白血病细胞系中的酪氨酸激酶抑制剂耐药性：耐药途径的研究。
Leuk Lymphoma. 2011 Nov;52(11):2139-47. doi: 10.3109/10428194.2011.591013. Epub 2011 Jun 30.
6
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.增强 T315I-BCR-ABL 表达细胞中 ABL 抑制剂诱导的 MAPK 激活：改变白血病发生能力的潜在机制。
J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.
7
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.达沙替尼、尼洛替尼、雷帕霉素和硼替佐米逆转 Bcr-Abl 阳性伊马替尼耐药细胞系 K562r 中伊马替尼耐药的研究。
Int J Lab Hematol. 2011 Apr;33(2):176-81. doi: 10.1111/j.1751-553X.2010.01267.x. Epub 2010 Oct 4.
8
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.BCR-ABL抑制剂伊马替尼、尼洛替尼和达沙替尼的化学蛋白质组学图谱揭示了新的激酶和非激酶靶点。
Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24.
9
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.MEK1/2抑制剂使Bcr/Abl+人白血病细胞对双重Abl/Src抑制剂BMS-354/825敏感。
Blood. 2007 May 1;109(9):4006-15. doi: 10.1182/blood-2006-09-045039. Epub 2007 Jan 11.
10
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.AP24163 抑制 BCR-ABL 的守门员突变体并抑制体外耐药性。
Chem Biol Drug Des. 2010 Feb;75(2):223-7. doi: 10.1111/j.1747-0285.2009.00911.x. Epub 2009 Dec 17.
引用本文的文献
1
The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.基于底物的激酶抑制剂改善靶点选择性和克服耐药性的前景。
Chem Sci. 2024 Jul 13;15(33):13130-13147. doi: 10.1039/d4sc01088d. eCollection 2024 Aug 22.
2
Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.靶向 STAT5 或 STAT5 调控的通路可抑制 Ph+ 急性淋巴细胞白血病的白血病发生。
Cancer Res. 2018 Oct 15;78(20):5793-5807. doi: 10.1158/0008-5472.CAN-18-0195. Epub 2018 Aug 28.
3
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.新型酪氨酸激酶抑制剂在慢性髓性白血病中的作用
Cancer J. 2016 Jan-Feb;22(1):40-50. doi: 10.1097/PPO.0000000000000165.
4
Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.蛋白激酶的小分子底物磷酸化位点抑制剂：方法与挑战
ACS Chem Biol. 2015 Jan 16;10(1):175-89. doi: 10.1021/cb5008376. Epub 2014 Dec 23.
5
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.分子动力学揭示 BCR-ABL1 多突变体是对泛 BCR-ABL1 激酶抑制剂治疗产生耐药性的独特机制。
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3550-5. doi: 10.1073/pnas.1321173111. Epub 2014 Feb 18.
6
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells. sestrin 3（SESN3）在表达 BCR-ABL 的细胞中的调节作用。
PLoS One. 2013 Nov 18;8(11):e78780. doi: 10.1371/journal.pone.0078780. eCollection 2013.
7
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.AMPK 激活剂对表达 BCR-ABL 的细胞的抗白血病作用。
Blood. 2011 Dec 8;118(24):6399-402. doi: 10.1182/blood-2011-01-332783. Epub 2011 Oct 21.
8
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.mTORC2-和雷帕霉素不敏感的 mTORC1 复合物在表达 BCR-ABL 的白血病细胞的生长和存活中发挥关键作用。
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12469-74. doi: 10.1073/pnas.1005114107. Epub 2010 Jun 28.
本文引用的文献
1
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.伊马替尼耐药的BCR-ABL突变阴性白血病与LYN激酶持续激活之间的关联。
J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.
2
Metabolism and disposition of dasatinib after oral administration to humans.达沙替尼口服给药后在人体内的代谢与处置。
Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17.
3
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.甲磺酸伊马替尼治疗失败后慢性髓性白血病伴T315I突变患者的特征及转归
Blood. 2008 Jul 1;112(1):53-5. doi: 10.1182/blood-2007-11-123950. Epub 2008 Apr 10.
4
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.Lyn调节伊马替尼耐药慢性粒细胞白血病细胞中的BCR-ABL和Gab2酪氨酸磷酸化以及c-Cbl蛋白稳定性。
Blood. 2008 Apr 1;111(7):3821-9. doi: 10.1182/blood-2007-08-109330. Epub 2008 Jan 30.
5
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.BCR-ABL抑制剂伊马替尼、尼洛替尼和达沙替尼的化学蛋白质组学图谱揭示了新的激酶和非激酶靶点。
Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24.
6
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.WP1130激活一种新的Bcr/Abl降解途径可诱导慢性粒细胞白血病细胞凋亡。
Blood. 2007 Apr 15;109(8):3470-8. doi: 10.1182/blood-2006-02-005579. Epub 2007 Jan 3.
7
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.一种非ATP竞争性的BCR-ABL抑制剂可克服伊马替尼耐药性。
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1992-7. doi: 10.1073/pnas.0408283102. Epub 2005 Jan 27.
8
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.对STI571耐药的慢性粒细胞白血病细胞中的BCR-ABL独立性和LYN激酶过表达
Blood. 2003 Jan 15;101(2):690-8. doi: 10.1182/blood.V101.2.690.
Zotero 插件